A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322

NCT01686711 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

207

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus

Interventions

DRUG: AD-4833 15 mg
DRUG: AD-4833 30 mg
DRUG: Placebo

Sponsor

Takeda